USD
$0.00
(0.00%
)At Close (As of Sep 15, 2025)
$70.90M
Market Cap
-
P/E Ratio
-13.27
EPS
$46.80
52 Week High
$3.76
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $3.9M |
Total Revenue | $3.9M |
Cost Of Revenue | $2.6M |
Costof Goods And Services Sold | $2.6M |
Operating Income | -$89M |
Selling General And Administrative | $23M |
Research And Development | $70M |
Operating Expenses | $93M |
Investment Income Net | - |
Net Interest Income | $4.4M |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | -$131M |
Income Tax Expense | $331K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$131M |
Comprehensive Income Net Of Tax | - |
Ebit | -$89M |
Ebitda | -$89M |
Net Income | -$131M |
Field | Value (USD) |
---|---|
Total Assets | $70M |
Total Current Assets | $62M |
Cash And Cash Equivalents At Carrying Value | $37M |
Cash And Short Term Investments | $37M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $8M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $20M |
Other Current Assets | $5.2M |
Other Non Current Assets | - |
Total Liabilities | $99M |
Total Current Liabilities | $22M |
Current Accounts Payable | $2.6M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $3.5M |
Total Non Current Liabilities | $77M |
Capital Lease Obligations | $8.4M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $8.4M |
Other Current Liabilities | $14M |
Other Non Current Liabilities | $46K |
Total Shareholder Equity | -$29M |
Treasury Stock | - |
Retained Earnings | -$618M |
Common Stock | $8K |
Common Stock Shares Outstanding | $6.3M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$81M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $2.6M |
Capital Expenditures | $130K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$18M |
Cashflow From Financing | $355K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$131M |
Field | Value (USD) |
---|---|
Gross Profit | $3.9M |
Total Revenue | $3.9M |
Cost Of Revenue | $2.6M |
Costof Goods And Services Sold | $2.6M |
Operating Income | -$89M |
Selling General And Administrative | $23M |
Research And Development | $70M |
Operating Expenses | $93M |
Investment Income Net | - |
Net Interest Income | $4.4M |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | - |
Income Before Tax | -$131M |
Income Tax Expense | $331K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$131M |
Comprehensive Income Net Of Tax | - |
Ebit | -$89M |
Ebitda | -$89M |
Net Income | -$131M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.